Uterine myomas are the most prevalent benign gynecological tumors,affecting over 70%of women[1].They are often associated with significant morbidity,including anemia and infertility.In contrast,uterine sarcomas,althou...Uterine myomas are the most prevalent benign gynecological tumors,affecting over 70%of women[1].They are often associated with significant morbidity,including anemia and infertility.In contrast,uterine sarcomas,although rare,are highly malignant,with a five-year survival rate of 50%-55%in early stages and a stark decline to 8%-12%in advanced stages[2],[3].展开更多
基金supported by the Independent Research Fund of the State Key Laboratory of Complex,Severe,and Rare Diseases(2025-I-PY-010)Beijing Municipal Natural Science Foundation(Z220013)+4 种基金the National Natural Science Foundation of China(82271656,82530054,and 82171621)the National Key R&D Program of China(2023YFC2706001)the National High Level Hospital Clinical Research Funding(2025-PUMCH-C-037 and 2022-PUMCHC-060)CAMS Initiative for Innovative Medicine(2021-I2M-1-004)Barnhart Family Distinguished Professorship from the University of Texas MD Anderson Cancer Center.
文摘Uterine myomas are the most prevalent benign gynecological tumors,affecting over 70%of women[1].They are often associated with significant morbidity,including anemia and infertility.In contrast,uterine sarcomas,although rare,are highly malignant,with a five-year survival rate of 50%-55%in early stages and a stark decline to 8%-12%in advanced stages[2],[3].
基金supported by the National Natural Science Foundation of China(32270774,31671400,81971439,32070694,31571436,31872822,and 31301153)the National Key Research and Development Program of China(2017YFA0503502,2016YFA0500903,2021YFC2700200,2017YFA0504600,and 2019YFA0508700)funded by the National Institutes of Health Office of Research Infrastructure Programs(P40 OD010440)。
